ArticleJournal of lipid research2025
Multiomics analysis to evaluate the enrichment of extracellular vesicles from human plasma.
Article in Journal of lipid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating mass spectrometry-based multi-omic signatures of extracellular vesicles: from discovery to clinical translation.Clinical & translational immunology · 2026Review
- Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) in blood plasma offer a valuable reservoir of intracellular cellular cargo, making them a promising source of liquid-based biomarkers. However, the complexity of plasma, with its abundance of non-EV particles and plasma proteins, presents challenges for their molecular characterization, particular their lipid composition, using mass spectrometry-based technologies. Consequently, there is currently no comprehensive blueprint detailing both the proteomes and lipidomes of highly enriched plasma EVs. We employed an orthogonal approach using density gradient ultracentrifugation (DGUC) and size-exclusion chromatography (SEC) to isolate EVs and conducted a comparative study on four different SEC columns following DGUC to evaluate the capacity of the SEC columns in enriching EVs while depleting plasma proteins and lipoprotein particles. The EV fractions were analyzed with data-independent acquisition proteomics and nano-ESI-ultrahigh-resolution accurate mass spectrometric lipidomics. DGUC followed by the appropriated sized SEC provided the best enrichment of EVs and the corresponding depletion of plasma protein and lipoprotein particle contaminants. We show that glycerophosphoethanoamine, glycerophosphoserine, ceramide, and sphingomyelin lipids are significantly enriched, while cholesteryl ester content is significantly depleted in EVs compared to platelet depleted plasma. This strategy also enabled the detection of proteins in the enriched EV fractions with functions related to mitochondria, endosomal-autophagic-lysosomal pathways, and the central nervous system. This study highlights the benefit of depleting coisolates from plasma EV preparations to enable the detection of proteins and lipids with potential future clinical utility and underscores the need for ongoing development of improved high-throughput EV isolation technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.